KALVISTA PHARMACEUTICALS INC's ticker is KALV and the CUSIP is 483497103.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $627,433 | +7.0% | 65,154 | 0.0% | 0.00% | – |
| Q2 2023 | $586,386 | +16.8% | 65,154 | +2.0% | 0.00% | – |
| Q1 2023 | $501,995 | +17.7% | 63,867 | +1.2% | 0.00% | – |
| Q4 2022 | $426,664 | -53.4% | 63,116 | 0.0% | 0.00% | – |
| Q3 2022 | $916,000 | +48.0% | 63,116 | +0.3% | 0.00% | – |
| Q2 2022 | $619,000 | -28.2% | 62,899 | +7.7% | 0.00% | – |
| Q1 2022 | $862,000 | +13.4% | 58,415 | +1.7% | 0.00% | – |
| Q4 2021 | $760,000 | -16.5% | 57,415 | +10.2% | 0.00% | – |
| Q3 2021 | $910,000 | -21.1% | 52,098 | +8.2% | 0.00% | – |
| Q2 2021 | $1,154,000 | -4.2% | 48,161 | +2.7% | 0.00% | – |
| Q1 2021 | $1,205,000 | +88.9% | 46,897 | +39.6% | 0.00% | – |
| Q4 2020 | $638,000 | +63.2% | 33,587 | +8.4% | 0.00% | – |
| Q3 2020 | $391,000 | -0.5% | 30,990 | -4.4% | 0.00% | – |
| Q2 2020 | $393,000 | +71.6% | 32,421 | +8.7% | 0.00% | – |
| Q1 2020 | $229,000 | -57.0% | 29,829 | 0.0% | 0.00% | – |
| Q4 2019 | $532,000 | +67.8% | 29,829 | +9.3% | 0.00% | – |
| Q3 2019 | $317,000 | -47.6% | 27,293 | 0.0% | 0.00% | – |
| Q2 2019 | $605,000 | – | 27,293 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Prosight Management, LP | 589,270 | $8,686,000 | 5.61% |
| GREAT POINT PARTNERS LLC | 874,197 | $12,886,000 | 3.11% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 383,233 | $10,805,000 | 2.44% |
| Frazier Life Sciences Management, L.P. | 1,572,192 | $23,174,000 | 1.98% |
| TANG CAPITAL MANAGEMENT LLC | 648,269 | $9,555,000 | 1.91% |
| Deep Track Capital, LP | 1,729,757 | $25,497,000 | 1.64% |
| Vivo Capital, LLC | 1,533,559 | $22,605,000 | 1.56% |
| Monashee Investment Management LLC | 264,111 | $3,893,000 | 1.13% |
| COMMODORE CAPITAL LP | 312,553 | $4,607,000 | 1.03% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,746,300 | $25,740,000 | 0.79% |